Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18270262 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Richardson C, et al. (2008) Activation of the thiazide-sensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci 121, 675-84 18270262
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T46-p - NCCT (human) ▲
Orthologous residues
NCCT (human): T46‑p, NCCT (mouse): T44‑p, NCCT (rat): T44‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE OSR1 (human)
KINASE STLK3 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T55-p - NCCT (human) ▲
Orthologous residues
NCCT (human): T55‑p, NCCT (mouse): T53‑p, NCCT (rat): T53‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE OSR1 (human)
KINASE STLK3 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T60-p - NCCT (human) ▲
Orthologous residues
NCCT (human): T60‑p, NCCT (mouse): T58‑p, NCCT (rat): T58‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE STLK3 (human)
KINASE OSR1 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  activation

S91-p - NCCT (human) ▲
Orthologous residues
NCCT (human): S91‑p, NCCT (mouse): S89‑p, NCCT (rat): S89‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T185-p - OSR1 (human) ▲
Orthologous residues
OSR1 (human): T185‑p, OSR1 (mouse): T185‑p, OSR1 (rat): T185‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S325-p - OSR1 (human) ▲
Orthologous residues
OSR1 (human): S325‑p, OSR1 (mouse): S325‑p, OSR1 (rat): S325‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T231-p - STLK3 (human) ▲
Orthologous residues
STLK3 (human): T231‑p, STLK3 (mouse): T243‑p, STLK3 (rat): T240‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S371-p - STLK3 (human) ▲
Orthologous residues
STLK3 (human): S371‑p, STLK3 (mouse): S383‑p, STLK3 (rat): S380‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S382-p - WNK1 (human) ▲
Orthologous residues
WNK1 (human): S382‑p, WNK1 iso4 (human): S382‑p, WNK1 (mouse): S382‑p, WNK1 iso3 (mouse): S382‑p, WNK1 iso8 (mouse): ‑, WNK1 (rat): S382‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T44-p - NCCT (mouse) ▲
Orthologous residues
NCCT (human): T46‑p, NCCT (mouse): T44‑p, NCCT (rat): T44‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  mpkCCD (renal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T53-p - NCCT (mouse) ▲
Orthologous residues
NCCT (human): T55‑p, NCCT (mouse): T53‑p, NCCT (rat): T53‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  mpkCCD (renal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T58-p - NCCT (mouse) ▲
Orthologous residues
NCCT (human): T60‑p, NCCT (mouse): T58‑p, NCCT (rat): T58‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  mpkCCD (renal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T185-p - OSR1 (mouse) ▲
Orthologous residues
OSR1 (human): T185‑p, OSR1 (mouse): T185‑p, OSR1 (rat): T185‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

S325-p - OSR1 (mouse) ▲
Orthologous residues
OSR1 (human): S325‑p, OSR1 (mouse): S325‑p, OSR1 (rat): S325‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

S382-p - WNK1 (mouse) ▲
Orthologous residues
WNK1 (human): S382‑p, WNK1 iso4 (human): S382‑p, WNK1 (mouse): S382‑p, WNK1 iso3 (mouse): S382‑p, WNK1 iso8 (mouse): ‑, WNK1 (rat): S382‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

T240-p - STLK3 (rat) ▲
Orthologous residues
STLK3 (human): T231‑p, STLK3 (mouse): T243‑p, STLK3 (rat): T240‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase

S380-p - STLK3 (rat) ▲
Orthologous residues
STLK3 (human): S371‑p, STLK3 (mouse): S383‑p, STLK3 (rat): S380‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypotonic buffer increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.